triptorelin  (Millipore)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91
    Name:
    Triptorelin Related Compound C
    Description:
    This product is provided as delivered and specified by the issuing Pharmacopoeia All information provided in support of this product including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia For further information and support please go to the website of the issuing Pharmacopoeia
    Catalog Number:
    1696142
    Price:
    None
    Buy from Supplier


    Structured Review

    Millipore triptorelin
    The level of p-ERK1/2 is influenced by integration of signaling from multiple cell surface receptors, blocking the response to activated GnRH receptor . A. <t>Triptorelin</t> did not affect levels of p-ERK1/2 in serum-starved MCF-7-30 or MDA-MB-231-34 cells. B. Treatment of stably transfected cells with 100 nM Triptorelin transiently elevated levels of phosphorylated ERK1/2 (p-ERK1/2) in serum-starved MCF-7-30-7hygro14 cells but not in the presence of serum. Bar graphs indicate effect of no serum vs with serum on ERK response in MCF7hygro14, statistically significant for no serum, p
    This product is provided as delivered and specified by the issuing Pharmacopoeia All information provided in support of this product including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia For further information and support please go to the website of the issuing Pharmacopoeia
    https://www.bioz.com/result/triptorelin/product/Millipore
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    triptorelin - by Bioz Stars, 2021-09
    91/100 stars

    Images

    1) Product Images from "GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines"

    Article Title: GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines

    Journal: BMC Cancer

    doi: 10.1186/1471-2407-11-476

    The level of p-ERK1/2 is influenced by integration of signaling from multiple cell surface receptors, blocking the response to activated GnRH receptor . A. Triptorelin did not affect levels of p-ERK1/2 in serum-starved MCF-7-30 or MDA-MB-231-34 cells. B. Treatment of stably transfected cells with 100 nM Triptorelin transiently elevated levels of phosphorylated ERK1/2 (p-ERK1/2) in serum-starved MCF-7-30-7hygro14 cells but not in the presence of serum. Bar graphs indicate effect of no serum vs with serum on ERK response in MCF7hygro14, statistically significant for no serum, p
    Figure Legend Snippet: The level of p-ERK1/2 is influenced by integration of signaling from multiple cell surface receptors, blocking the response to activated GnRH receptor . A. Triptorelin did not affect levels of p-ERK1/2 in serum-starved MCF-7-30 or MDA-MB-231-34 cells. B. Treatment of stably transfected cells with 100 nM Triptorelin transiently elevated levels of phosphorylated ERK1/2 (p-ERK1/2) in serum-starved MCF-7-30-7hygro14 cells but not in the presence of serum. Bar graphs indicate effect of no serum vs with serum on ERK response in MCF7hygro14, statistically significant for no serum, p

    Techniques Used: Blocking Assay, Multiple Displacement Amplification, Stable Transfection, Transfection

    Dynamics of GnRH receptor activation following treatment with Triptorelin . Treatment of stably transfected cells with GnRH elicited high levels of 3 H- inositol phosphate (IP) production (A-C). Removal of GnRH and LiCl revealed the dynamics of 3 H- inositol phosphate turnover in different cell types (D,E). The decrease in levels of 3 H- inositol phosphates was slower in SVCT-2 cells. Statistically different values (p
    Figure Legend Snippet: Dynamics of GnRH receptor activation following treatment with Triptorelin . Treatment of stably transfected cells with GnRH elicited high levels of 3 H- inositol phosphate (IP) production (A-C). Removal of GnRH and LiCl revealed the dynamics of 3 H- inositol phosphate turnover in different cell types (D,E). The decrease in levels of 3 H- inositol phosphates was slower in SVCT-2 cells. Statistically different values (p

    Techniques Used: Activation Assay, Stable Transfection, Transfection

    The effect of Triptorelin on growth of cells stably transfected with GnRH . A. Growth of SVCT-2 after 4 days was marginally inhibited (10-18%) by treatment with Triptorelin. However, cell growth was effectively inhibited by IGF-IR inhibitor II and co-treatment with Triptorelin exerted a small additive effect (B). EGFR/ErbB2 inhibitor reduced SVCT-2 cell growth, but co-treatment with Triptorelin had no effect (C). Growth of MCF-7-30-7hygro14 cells was not affected by treatment with 100 nM Triptorelin (D), unlike HEK293 [SCL60] cells (E) after 4 days. Growth and survival were inhibited by IGF-IR inhibitor II but co-treatment with Triptorelin had no effect (F). Transient exposure to 15 μM IGF-IR inhibitor II for up to 2 hours resulted in less than 10% growth-inhibition after 4 days, longer exposures resulted in more extensive growth-inhibition (G). Growth of MCF-7-30-7hygro14 cells was inhibited by EGFR/ErbB2 inhibitor but not affected by treatment with 7 μM PI3Kγ inhibitor and co-treatment with 100 nM Triptorelin exerted no significant growth-inhibition (H and I). Growth of ZR75-1-12 (J) and MDA-MB-231-34 (K) was unaffected by treatment with 100 nM Triptorelin. * p
    Figure Legend Snippet: The effect of Triptorelin on growth of cells stably transfected with GnRH . A. Growth of SVCT-2 after 4 days was marginally inhibited (10-18%) by treatment with Triptorelin. However, cell growth was effectively inhibited by IGF-IR inhibitor II and co-treatment with Triptorelin exerted a small additive effect (B). EGFR/ErbB2 inhibitor reduced SVCT-2 cell growth, but co-treatment with Triptorelin had no effect (C). Growth of MCF-7-30-7hygro14 cells was not affected by treatment with 100 nM Triptorelin (D), unlike HEK293 [SCL60] cells (E) after 4 days. Growth and survival were inhibited by IGF-IR inhibitor II but co-treatment with Triptorelin had no effect (F). Transient exposure to 15 μM IGF-IR inhibitor II for up to 2 hours resulted in less than 10% growth-inhibition after 4 days, longer exposures resulted in more extensive growth-inhibition (G). Growth of MCF-7-30-7hygro14 cells was inhibited by EGFR/ErbB2 inhibitor but not affected by treatment with 7 μM PI3Kγ inhibitor and co-treatment with 100 nM Triptorelin exerted no significant growth-inhibition (H and I). Growth of ZR75-1-12 (J) and MDA-MB-231-34 (K) was unaffected by treatment with 100 nM Triptorelin. * p

    Techniques Used: Stable Transfection, Transfection, Inhibition, Multiple Displacement Amplification

    2) Product Images from "Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats"

    Article Title: Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    doi: 10.1073/pnas.211442598

    Effects of a single dose of cetrorelix, triptorelin, and their combinations on the pituitary LHRH-R mRNA expression and serum LH concentration in normal rats. ( a ) LHRH-R mRNA level; ( b ) RT-PCR products of the pituitary LHRH-R mRNA and β-actin mRNA, after separation by agarose gel electrophoresis and staining with ethidium bromide. M, 100-bp DNA molecular weight marker; lanes 1 and 2,100 μg of cetrorelix; lanes 3 and 4, 10 μg of triptorelin; lanes 5 and 6, 100 μg of cetrorelix and 10 μg of triptorelin; lanes 7 and 8, 100 μg of triptorelin; lanes 9 and 10, 100 μg of cetrorelix and 100 μg of triptorelin; lanes 11 and 12, untreated controls. ( c ) Serum LH concentration. +, P
    Figure Legend Snippet: Effects of a single dose of cetrorelix, triptorelin, and their combinations on the pituitary LHRH-R mRNA expression and serum LH concentration in normal rats. ( a ) LHRH-R mRNA level; ( b ) RT-PCR products of the pituitary LHRH-R mRNA and β-actin mRNA, after separation by agarose gel electrophoresis and staining with ethidium bromide. M, 100-bp DNA molecular weight marker; lanes 1 and 2,100 μg of cetrorelix; lanes 3 and 4, 10 μg of triptorelin; lanes 5 and 6, 100 μg of cetrorelix and 10 μg of triptorelin; lanes 7 and 8, 100 μg of triptorelin; lanes 9 and 10, 100 μg of cetrorelix and 100 μg of triptorelin; lanes 11 and 12, untreated controls. ( c ) Serum LH concentration. +, P

    Techniques Used: Expressing, Concentration Assay, Reverse Transcription Polymerase Chain Reaction, Agarose Gel Electrophoresis, Staining, Molecular Weight, Marker

    In vitro effects of LHRH, triptorelin, cetrorelix, and their combinations on LHRH-R expression and LH secretion from rat pituitary cells in the superfusion system. ( a ) LHRH-R mRNA levels after an exposure of the cells to 3-min pulses of 1 nM LHRH and 0.1 nM triptorelin for 5 h, a continuous perfusion with 50 nM cetrorelix for 5 h, and a coperfusion with 50 nM cetrorelix and 1 nM LHRH or 0.1 nM triptorelin. **, P
    Figure Legend Snippet: In vitro effects of LHRH, triptorelin, cetrorelix, and their combinations on LHRH-R expression and LH secretion from rat pituitary cells in the superfusion system. ( a ) LHRH-R mRNA levels after an exposure of the cells to 3-min pulses of 1 nM LHRH and 0.1 nM triptorelin for 5 h, a continuous perfusion with 50 nM cetrorelix for 5 h, and a coperfusion with 50 nM cetrorelix and 1 nM LHRH or 0.1 nM triptorelin. **, P

    Techniques Used: In Vitro, Expressing

    Pituitary LHRH-R mRNA expression and serum LH concentration during and after treatment for 10 days with a depot formulation of cetrorelix pamoate, releasing 100 μg/day or repeated daily injection of 100 μg of triptorelin. ( a ) LHRH-R mRNA level after the treatment. ( b ) RT-PCR products of the pituitary LHRH-R mRNA and β-actin mRNA after separation by agarose gel electrophoresis and staining with ethidium bromide. M, 100-bp DNA molecular weight marker; lanes 1–3, cetrorelix-treated; lanes 4–6, triptorelin-treated; lanes 7–9, untreated control. ( c ) Serum LH during the treatment. **, P
    Figure Legend Snippet: Pituitary LHRH-R mRNA expression and serum LH concentration during and after treatment for 10 days with a depot formulation of cetrorelix pamoate, releasing 100 μg/day or repeated daily injection of 100 μg of triptorelin. ( a ) LHRH-R mRNA level after the treatment. ( b ) RT-PCR products of the pituitary LHRH-R mRNA and β-actin mRNA after separation by agarose gel electrophoresis and staining with ethidium bromide. M, 100-bp DNA molecular weight marker; lanes 1–3, cetrorelix-treated; lanes 4–6, triptorelin-treated; lanes 7–9, untreated control. ( c ) Serum LH during the treatment. **, P

    Techniques Used: Expressing, Concentration Assay, Injection, Reverse Transcription Polymerase Chain Reaction, Agarose Gel Electrophoresis, Staining, Molecular Weight, Marker

    Pituitary LHRH-R mRNA expression and serum LH in OVX rats during and after the treatment for 10 days with a depot formulation of cetrorelix pamoate, releasing 100 μg/day or repeated daily injection of 100 μg of triptorelin. ( a ) LHRH-R mRNA level. ( b ) RT-PCR products of the pituitary LHRH-R mRNA and β-actin mRNA after separation by agarose gel electrophoresis and staining with ethidium bromide. M, 100-bp DNA molecular weight marker; lanes 1–3, cetrorelix-treated; lanes 4–6, triptorelin-treated; lanes 7–9, untreated control. ( c ) Serum LH during the treatment. **, P
    Figure Legend Snippet: Pituitary LHRH-R mRNA expression and serum LH in OVX rats during and after the treatment for 10 days with a depot formulation of cetrorelix pamoate, releasing 100 μg/day or repeated daily injection of 100 μg of triptorelin. ( a ) LHRH-R mRNA level. ( b ) RT-PCR products of the pituitary LHRH-R mRNA and β-actin mRNA after separation by agarose gel electrophoresis and staining with ethidium bromide. M, 100-bp DNA molecular weight marker; lanes 1–3, cetrorelix-treated; lanes 4–6, triptorelin-treated; lanes 7–9, untreated control. ( c ) Serum LH during the treatment. **, P

    Techniques Used: Expressing, Injection, Reverse Transcription Polymerase Chain Reaction, Agarose Gel Electrophoresis, Staining, Molecular Weight, Marker

    Related Articles

    other:

    Article Title: GnRH regulates the expression of its receptor accessory protein SET in pituitary gonadotropes
    Article Snippet: GnRH agonist ([D-Trp6 ]GnRH, triptorelin), poly-L-lysine, GF109203X and proteasome inhibitor MG132 were purchased from Sigma-Aldrich Chemie (Saint-Quentin Fallavier, France).

    Article Title: GnRH regulates the expression of its receptor accessory protein SET in pituitary gonadotropes
    Article Snippet: Materials and antibodies GnRH agonist ([D-Trp6 ]GnRH, triptorelin), poly-L-lysine, GF109203X and proteasome inhibitor MG132 were purchased from Sigma-Aldrich Chemie (Saint-Quentin Fallavier, France).

    In Vitro:

    Article Title: Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats
    Article Snippet: .. For in vitro experiments, cetrorelix, triptorelin, and the synthetic LHRH decapeptide were dissolved in medium 199 (Sigma). ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91
    Millipore triptorelin
    The level of p-ERK1/2 is influenced by integration of signaling from multiple cell surface receptors, blocking the response to activated GnRH receptor . A. <t>Triptorelin</t> did not affect levels of p-ERK1/2 in serum-starved MCF-7-30 or MDA-MB-231-34 cells. B. Treatment of stably transfected cells with 100 nM Triptorelin transiently elevated levels of phosphorylated ERK1/2 (p-ERK1/2) in serum-starved MCF-7-30-7hygro14 cells but not in the presence of serum. Bar graphs indicate effect of no serum vs with serum on ERK response in MCF7hygro14, statistically significant for no serum, p
    Triptorelin, supplied by Millipore, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/triptorelin/product/Millipore
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    triptorelin - by Bioz Stars, 2021-09
    91/100 stars
      Buy from Supplier

    Image Search Results


    The level of p-ERK1/2 is influenced by integration of signaling from multiple cell surface receptors, blocking the response to activated GnRH receptor . A. Triptorelin did not affect levels of p-ERK1/2 in serum-starved MCF-7-30 or MDA-MB-231-34 cells. B. Treatment of stably transfected cells with 100 nM Triptorelin transiently elevated levels of phosphorylated ERK1/2 (p-ERK1/2) in serum-starved MCF-7-30-7hygro14 cells but not in the presence of serum. Bar graphs indicate effect of no serum vs with serum on ERK response in MCF7hygro14, statistically significant for no serum, p

    Journal: BMC Cancer

    Article Title: GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines

    doi: 10.1186/1471-2407-11-476

    Figure Lengend Snippet: The level of p-ERK1/2 is influenced by integration of signaling from multiple cell surface receptors, blocking the response to activated GnRH receptor . A. Triptorelin did not affect levels of p-ERK1/2 in serum-starved MCF-7-30 or MDA-MB-231-34 cells. B. Treatment of stably transfected cells with 100 nM Triptorelin transiently elevated levels of phosphorylated ERK1/2 (p-ERK1/2) in serum-starved MCF-7-30-7hygro14 cells but not in the presence of serum. Bar graphs indicate effect of no serum vs with serum on ERK response in MCF7hygro14, statistically significant for no serum, p

    Article Snippet: Cells were treated with a dose range of Triptorelin or vehicle (20% propylene glycol, Sigma, UK).

    Techniques: Blocking Assay, Multiple Displacement Amplification, Stable Transfection, Transfection

    Dynamics of GnRH receptor activation following treatment with Triptorelin . Treatment of stably transfected cells with GnRH elicited high levels of 3 H- inositol phosphate (IP) production (A-C). Removal of GnRH and LiCl revealed the dynamics of 3 H- inositol phosphate turnover in different cell types (D,E). The decrease in levels of 3 H- inositol phosphates was slower in SVCT-2 cells. Statistically different values (p

    Journal: BMC Cancer

    Article Title: GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines

    doi: 10.1186/1471-2407-11-476

    Figure Lengend Snippet: Dynamics of GnRH receptor activation following treatment with Triptorelin . Treatment of stably transfected cells with GnRH elicited high levels of 3 H- inositol phosphate (IP) production (A-C). Removal of GnRH and LiCl revealed the dynamics of 3 H- inositol phosphate turnover in different cell types (D,E). The decrease in levels of 3 H- inositol phosphates was slower in SVCT-2 cells. Statistically different values (p

    Article Snippet: Cells were treated with a dose range of Triptorelin or vehicle (20% propylene glycol, Sigma, UK).

    Techniques: Activation Assay, Stable Transfection, Transfection

    The effect of Triptorelin on growth of cells stably transfected with GnRH . A. Growth of SVCT-2 after 4 days was marginally inhibited (10-18%) by treatment with Triptorelin. However, cell growth was effectively inhibited by IGF-IR inhibitor II and co-treatment with Triptorelin exerted a small additive effect (B). EGFR/ErbB2 inhibitor reduced SVCT-2 cell growth, but co-treatment with Triptorelin had no effect (C). Growth of MCF-7-30-7hygro14 cells was not affected by treatment with 100 nM Triptorelin (D), unlike HEK293 [SCL60] cells (E) after 4 days. Growth and survival were inhibited by IGF-IR inhibitor II but co-treatment with Triptorelin had no effect (F). Transient exposure to 15 μM IGF-IR inhibitor II for up to 2 hours resulted in less than 10% growth-inhibition after 4 days, longer exposures resulted in more extensive growth-inhibition (G). Growth of MCF-7-30-7hygro14 cells was inhibited by EGFR/ErbB2 inhibitor but not affected by treatment with 7 μM PI3Kγ inhibitor and co-treatment with 100 nM Triptorelin exerted no significant growth-inhibition (H and I). Growth of ZR75-1-12 (J) and MDA-MB-231-34 (K) was unaffected by treatment with 100 nM Triptorelin. * p

    Journal: BMC Cancer

    Article Title: GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines

    doi: 10.1186/1471-2407-11-476

    Figure Lengend Snippet: The effect of Triptorelin on growth of cells stably transfected with GnRH . A. Growth of SVCT-2 after 4 days was marginally inhibited (10-18%) by treatment with Triptorelin. However, cell growth was effectively inhibited by IGF-IR inhibitor II and co-treatment with Triptorelin exerted a small additive effect (B). EGFR/ErbB2 inhibitor reduced SVCT-2 cell growth, but co-treatment with Triptorelin had no effect (C). Growth of MCF-7-30-7hygro14 cells was not affected by treatment with 100 nM Triptorelin (D), unlike HEK293 [SCL60] cells (E) after 4 days. Growth and survival were inhibited by IGF-IR inhibitor II but co-treatment with Triptorelin had no effect (F). Transient exposure to 15 μM IGF-IR inhibitor II for up to 2 hours resulted in less than 10% growth-inhibition after 4 days, longer exposures resulted in more extensive growth-inhibition (G). Growth of MCF-7-30-7hygro14 cells was inhibited by EGFR/ErbB2 inhibitor but not affected by treatment with 7 μM PI3Kγ inhibitor and co-treatment with 100 nM Triptorelin exerted no significant growth-inhibition (H and I). Growth of ZR75-1-12 (J) and MDA-MB-231-34 (K) was unaffected by treatment with 100 nM Triptorelin. * p

    Article Snippet: Cells were treated with a dose range of Triptorelin or vehicle (20% propylene glycol, Sigma, UK).

    Techniques: Stable Transfection, Transfection, Inhibition, Multiple Displacement Amplification

    Effects of a single dose of cetrorelix, triptorelin, and their combinations on the pituitary LHRH-R mRNA expression and serum LH concentration in normal rats. ( a ) LHRH-R mRNA level; ( b ) RT-PCR products of the pituitary LHRH-R mRNA and β-actin mRNA, after separation by agarose gel electrophoresis and staining with ethidium bromide. M, 100-bp DNA molecular weight marker; lanes 1 and 2,100 μg of cetrorelix; lanes 3 and 4, 10 μg of triptorelin; lanes 5 and 6, 100 μg of cetrorelix and 10 μg of triptorelin; lanes 7 and 8, 100 μg of triptorelin; lanes 9 and 10, 100 μg of cetrorelix and 100 μg of triptorelin; lanes 11 and 12, untreated controls. ( c ) Serum LH concentration. +, P

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats

    doi: 10.1073/pnas.211442598

    Figure Lengend Snippet: Effects of a single dose of cetrorelix, triptorelin, and their combinations on the pituitary LHRH-R mRNA expression and serum LH concentration in normal rats. ( a ) LHRH-R mRNA level; ( b ) RT-PCR products of the pituitary LHRH-R mRNA and β-actin mRNA, after separation by agarose gel electrophoresis and staining with ethidium bromide. M, 100-bp DNA molecular weight marker; lanes 1 and 2,100 μg of cetrorelix; lanes 3 and 4, 10 μg of triptorelin; lanes 5 and 6, 100 μg of cetrorelix and 10 μg of triptorelin; lanes 7 and 8, 100 μg of triptorelin; lanes 9 and 10, 100 μg of cetrorelix and 100 μg of triptorelin; lanes 11 and 12, untreated controls. ( c ) Serum LH concentration. +, P

    Article Snippet: For in vitro experiments, cetrorelix, triptorelin, and the synthetic LHRH decapeptide were dissolved in medium 199 (Sigma).

    Techniques: Expressing, Concentration Assay, Reverse Transcription Polymerase Chain Reaction, Agarose Gel Electrophoresis, Staining, Molecular Weight, Marker

    In vitro effects of LHRH, triptorelin, cetrorelix, and their combinations on LHRH-R expression and LH secretion from rat pituitary cells in the superfusion system. ( a ) LHRH-R mRNA levels after an exposure of the cells to 3-min pulses of 1 nM LHRH and 0.1 nM triptorelin for 5 h, a continuous perfusion with 50 nM cetrorelix for 5 h, and a coperfusion with 50 nM cetrorelix and 1 nM LHRH or 0.1 nM triptorelin. **, P

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats

    doi: 10.1073/pnas.211442598

    Figure Lengend Snippet: In vitro effects of LHRH, triptorelin, cetrorelix, and their combinations on LHRH-R expression and LH secretion from rat pituitary cells in the superfusion system. ( a ) LHRH-R mRNA levels after an exposure of the cells to 3-min pulses of 1 nM LHRH and 0.1 nM triptorelin for 5 h, a continuous perfusion with 50 nM cetrorelix for 5 h, and a coperfusion with 50 nM cetrorelix and 1 nM LHRH or 0.1 nM triptorelin. **, P

    Article Snippet: For in vitro experiments, cetrorelix, triptorelin, and the synthetic LHRH decapeptide were dissolved in medium 199 (Sigma).

    Techniques: In Vitro, Expressing

    Pituitary LHRH-R mRNA expression and serum LH concentration during and after treatment for 10 days with a depot formulation of cetrorelix pamoate, releasing 100 μg/day or repeated daily injection of 100 μg of triptorelin. ( a ) LHRH-R mRNA level after the treatment. ( b ) RT-PCR products of the pituitary LHRH-R mRNA and β-actin mRNA after separation by agarose gel electrophoresis and staining with ethidium bromide. M, 100-bp DNA molecular weight marker; lanes 1–3, cetrorelix-treated; lanes 4–6, triptorelin-treated; lanes 7–9, untreated control. ( c ) Serum LH during the treatment. **, P

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats

    doi: 10.1073/pnas.211442598

    Figure Lengend Snippet: Pituitary LHRH-R mRNA expression and serum LH concentration during and after treatment for 10 days with a depot formulation of cetrorelix pamoate, releasing 100 μg/day or repeated daily injection of 100 μg of triptorelin. ( a ) LHRH-R mRNA level after the treatment. ( b ) RT-PCR products of the pituitary LHRH-R mRNA and β-actin mRNA after separation by agarose gel electrophoresis and staining with ethidium bromide. M, 100-bp DNA molecular weight marker; lanes 1–3, cetrorelix-treated; lanes 4–6, triptorelin-treated; lanes 7–9, untreated control. ( c ) Serum LH during the treatment. **, P

    Article Snippet: For in vitro experiments, cetrorelix, triptorelin, and the synthetic LHRH decapeptide were dissolved in medium 199 (Sigma).

    Techniques: Expressing, Concentration Assay, Injection, Reverse Transcription Polymerase Chain Reaction, Agarose Gel Electrophoresis, Staining, Molecular Weight, Marker

    Pituitary LHRH-R mRNA expression and serum LH in OVX rats during and after the treatment for 10 days with a depot formulation of cetrorelix pamoate, releasing 100 μg/day or repeated daily injection of 100 μg of triptorelin. ( a ) LHRH-R mRNA level. ( b ) RT-PCR products of the pituitary LHRH-R mRNA and β-actin mRNA after separation by agarose gel electrophoresis and staining with ethidium bromide. M, 100-bp DNA molecular weight marker; lanes 1–3, cetrorelix-treated; lanes 4–6, triptorelin-treated; lanes 7–9, untreated control. ( c ) Serum LH during the treatment. **, P

    Journal: Proceedings of the National Academy of Sciences of the United States of America

    Article Title: Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats

    doi: 10.1073/pnas.211442598

    Figure Lengend Snippet: Pituitary LHRH-R mRNA expression and serum LH in OVX rats during and after the treatment for 10 days with a depot formulation of cetrorelix pamoate, releasing 100 μg/day or repeated daily injection of 100 μg of triptorelin. ( a ) LHRH-R mRNA level. ( b ) RT-PCR products of the pituitary LHRH-R mRNA and β-actin mRNA after separation by agarose gel electrophoresis and staining with ethidium bromide. M, 100-bp DNA molecular weight marker; lanes 1–3, cetrorelix-treated; lanes 4–6, triptorelin-treated; lanes 7–9, untreated control. ( c ) Serum LH during the treatment. **, P

    Article Snippet: For in vitro experiments, cetrorelix, triptorelin, and the synthetic LHRH decapeptide were dissolved in medium 199 (Sigma).

    Techniques: Expressing, Injection, Reverse Transcription Polymerase Chain Reaction, Agarose Gel Electrophoresis, Staining, Molecular Weight, Marker